STIM1 and neoplasm: Clinically, STIM1 has been correlated with poor prognosis in breast (Yang et al., 2017), colorectal (Wang et al., 2015), and lung carcinoma (Zhan et al., 2015) because its overexpression in patients’ tissues is associated with increased tumor size, lymphatic metastases, and other factors.